

Dear Madam/Sir,

Please find below our comments on the Consultation paper:

Consultation item no° 1: we agree with the approach. GMP for active ingredient is already part of ICH Q7 and of GMP (Part II). It is therefore important to align the European Directive laying down the corresponding principles.

Consultation item no° 2: Article 5 - Compliance with marketing authorisation of the Directive 2003/94/EC should also be listed under item 13. The finished product manufacturer can and should ensure compliance with the marketing authorisation. The active ingredient manufacturer does not have access to the MA dossier, but commits to inform the finished product manufacturer of any changes.

Consultation item no° 3: yes, we consider the list complete.

Consultation item n° 4: yes, we agree with specific item 16.

Consultation item n°5: We do not pronounce ourselves on this specific item.

With our best regards / Cordialement / Mit freundlichen Grüßen / Saludos / Cordiali saluti

ITC - Technical Regulatory Intelligence Pharma Team
Representing Bayer Healthcare, Consumer Care Division, Global Technical Regulatory Affairs

Bayer HealthCare Consumer Care

Bayer Santé Familiale S.A.S.
ITC / GTRA
33, rue de l'Industrie
74240 Gaillard, France

itc-pharma_veille-reglementaire.bsf@bayer.com

Les informations contenues dans ce courriel sont destinées à l'usage exclusif du (des) destinataire(s) et peuvent être confidentielles, déposées et (ou) faire l'objet juridiquement d'un privilège. La divulgation accidentelle de ce message ne constitue pas une renonciation à un privilège quelconque. Si vous recevez ce message par erreur, veuillez ne pas l'utiliser, directement ou indirectement, ni l'imprimer, le copier, le faire suivre ou le divulguer, même partiellement. Veuillez aussi détruire ce courriel avec toutes ses copies et avertir son expéditeur. Merci.

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.
